An experimental drug designed to quickly counteract blood-thinning medicines has demonstrated effectiveness, according to preliminary results of a new trial done under real-world conditions.
The drug is Portola Pharmaceuticals’ AndexXa, known generically as andexanet alfa. Earlier this month, the U.S. Food and Drug Administration decided not to approve this so-called reversal agent without more data. The new test, reported on Tuesday at a European Society of Cardiology Congress in Rome and released by the New England Journal of Medicine, offers more evidence. Portola financed the study.
The drug reversed episodes of major bleeding that couldn’t be stopped because the patients were on drugs such as apixaban and rivaroxaban, which inhibit the body’s natural blood clotting chemical known as factor Xa.
Filed under: Uncategorized |